OOIR: Observatory of International Research

Papers

(The median citation count of Seminars in Hematology is 2. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-11-01 to 2025-11-01.)

Article	Citations
Special issue on chronic lymphocytic leukemia: Prognostication and therapeutic options introductory editorial	78
CAR T-cell therapy comes of age: Introductory editorial for the special issue	57
Clinical applications of circulating tumor DNA in Hodgkin lymphoma	52
Insights from the 12th International Workshop on Waldenstrom's Macroglobulinemia	50
Clonality in immune aplastic anemia: Mechanisms of immune escape or malignant transformation	49
Extramedullary myeloma in the era of CAR T-cell and bispecific antibody therapies	41
How to set up a clinical research center in Brazil, as an example of a middle-income country	41
The winding road: Infectious disease considerations for CAR-T and other novel adoptive cellular therapies in the era of COVID-19	25
Epidemiology and etiology of diffuse large B-cell lymphoma	24
The future of lymphoma diagnosis, prognosis, and treatment monitoring in countries with limited access to pathology services	21
Lessons learned from the Eµ-TCL1 mouse model of CLL	21
TET2 mutation as prototypic clonal hematopoiesis lesion	20
Somatic mutations in “benign” blood diseases	19
Antibody and immunotherapy in diffuse large B-cell lymphoma	18
The role of viruses in HIV-associated lymphomas	17
Immune-driven clonal cell selection at the intersection among cancer, infections, autoimmunity and senescence	17
Intestinal microbiome and myelodysplastic syndromes: Current state of knowledge and perspectives for future	15
Report of Consensus Panel 5 from the 12th International Workshop on Waldenstrom's Macroglobulinemia on the management of patients with intolerance or resistance to covalent BTK inhibitors	14
Vaccinations in patients with chronic lymphocytic leukemia	14
Accelerating accessibility of CAR-T/NK therapies – Are AlloCARs and rapid manufacturing platforms the road ahead in improving access in multiple myeloma?	14
The molecular map of CLL and Richter's syndrome	13
Clonal hematopoiesis	13
At the cusp of a cure in Myeloma: Insights into pathogenesis, modeling and therapeutics	13
outside front cover, PMS 8883 metallic AND 4/C	12
outside front cover, PMS 8883 metallic AND 4/C	12

Tribute to an editor: Neal S. Young As a Medical Editor and Writer	12
Cellular and immunotherapies for myelodysplastic syndromes	12
outside front cover, PMS 8883 metallic AND 4/C	11
B-cell receptor immunoglobulin stereotypy in chronic lymphocytic leukemia: Key to understanding disease biology and stratifying patients	11
Management of Myelodysplastic Syndrome in Pregnant Patients: Treatment Approaches and Considerations	11
Advancements in bispecific antibodies for multiple myeloma: What's new and what lies ahead	10
Report of Consensus Panel 3 from the 11th International workshop on Waldenström's Macroglobulinemia: Recommendations for molecular diagnosis in Waldenström's Macroglobulinemia	9
The biology of classical Hodgkin lymphoma	9
Aplastic anemia: Quo vadis?	9
Challenges and opportunities of CAR T-cell therapies for CLL	9
Access to essential therapy for sickle cell disease in Africa: Experience from a national program in Ghana	8
Menin inhibition for the treatment of acute leukemia	8
Somatic mutations in acquired pure red cell aplasia	8
The psychiatric and psychological sequelae of vaccine-induced immune thrombotic thrombocytopenia (VITT)	8
Mobilizing CARs: Benefits, drawbacks, and directions for outpatient CAR T-cell therapy	8
Somatic compensation of inherited bone marrow failure	8
A tower of babel of acronyms? The shadowlands of MGUS/MBL/CHIP/TCUS	8
Understanding MDS stem cells: Advances and limitations	8
The pediatric approach to Hodgkin lymphoma	8
The crossroads of cancer therapies and clonal hematopoiesis	7
DLBCL arising from indolent lymphomas: How are they different?	7
Report of consensus panel 7 from the 11th international workshop on Waldenström macroglobulinemia on priorities for novel clinical trials	7
Report of Consensus Panel 2 from the 12th International Workshop on the management of Bing-Neel syndrome in patients with Waldenstrom’s Macroglobulinemia	6
Clinical applications of circulating tumor DNA in central nervous system lymphoma	6
The spectrum of somatic mutations in large granular lymphocyte leukemia, rheumatoid arthritis, and Felty's syndrome	6
Modernizing multiple myeloma clinical trial eligibility to improve equity and inclusivity by hematological parameters	6
Collaborations, colleagues, and friendships: The Hematology Branch and blood disease centers in Asia	5
Measurable residual disease after CAR T-cell therapy	5
Infectious complications of chimeric antigen receptor (CAR) T-cell therapies	5
outside front cover, PMS 8883 metallic AND 4/C	5
Current challenges and new approaches to implementing optimal management of sickle cell disease in sub-Saharan Africa	5
Updates on the biology of chronic lymphocytic leukemia: introductory editorial	5
Clonal hematopoiesis in the setting of hematopoietic cell transplantation	5
Report of Consensus Panel 3 from the 12th International Workshop on Waldenstrom's Macroglobulinemia on the management of patients with high-risk disease	5
License for a CAR T: Examining patient eligibility	5
Report of consensus panel 2 from the 11th international workshop on Waldenström's macroglobulinemia on the management of relapsed or refractory WM patients	5
Report of consensus Panel 4 from the 11th International Workshop on Waldenstrom's macroglobulinemia on diagnostic and response criteria	5
Highlights of the 11th International Workshop on Waldenstrom's Macroglobulinemia: What we learned, and how it will impact scientific discovery and patient care	5
outside front cover, PMS 8883 metallic AND 4/C	5
miRNA Biology in Chronic Lymphocytic Leukemia	5
Forging international collaboration and alliances to establish the largest transplant center in the north of Vietnam	5
Hemolytic paroxysmal nocturnal hemoglobinuria: 20 years of medical progress	5
Report of consensus panel 1 from the 11th International Workshop on Waldenstrom's Macroglobulinemia on management of symptomatic, treatment-naïve patients	5
RNA splicing as a therapeutic target in myelodysplastic syndromes	4
Measurable residual disease monitoring in acute myeloid leukaemia: Techniques, timing and therapeutic implications	4
Special edition of the Seminars in Hematology series on Global Hematology Care	4
The role of autologous stem-cell transplantation in classical Hodgkin lymphoma in the modern era	4
AML diagnostics in the 21st century: Use of AI	4
Platelet-activating anti-PF4 disorders: An overview	4
Inflammation in myelodysplastic syndrome pathogenesis	4

Melanoma antigen genes (MAGE); novel functional targets in multiple myeloma	4
Characterization of anti-CD3 antibodies in clinically available bispecific T cell engagers	3
Inequalities in access to treatment in Argentina: Differences in management of CLL and multiple myeloma?	3
The Management of older patients with Hodgkin lymphoma: implications of S1826	3
The case for prioritizing malignant hematology services in low- and middle-income countries	3
The Road More or Less Traveled- Examining the Role of Consolidative Allogeneic Hematopoietic Stem Cell Transplantation After Chimeric Antigen Receptor T Cell Therapy in B-cell ALL	3
Resolving leukemic stem cell heterogeneity and plasticity with single-cell multiomics	3
The genomic landscape of acute myeloid leukemia: Redefining classifications, ontogeny, and therapeutic strategies	3
Role of the tumor microenvironment in CLL pathogenesis	3
Applications of virus-specific T cell therapies post-BMT	3
Special issue on circulating tumor DNA: Introductory editorial	3
Infections and antimicrobial prophylaxis in patients with myelodysplastic syndromes	3
Tuning CAR T-cell therapies for efficacy and reduced toxicity	3
Gene editing for sickle cell disease and transfusion dependent thalassemias- A cure within reach	2
outside front cover, PMS 8883 metallic AND 4/C	2
Patient-reported outcomes in early phase trials for patients with myelodysplastic syndromes	2
Tailoring intensive and less-intensive treatment in acute myeloid leukemia	2
Mouse models of CLL: In vivo modeling of disease initiation, progression, and transformation	2
Smoldering multiple myeloma: Integrating biology and risk into management	2
Secondary and therapy-related acute myeloid leukemias: Overlapping features, distinct trajectories	2
Pathogenesis of vaccine-induced immune thrombotic thrombocytopenia (VITT)	2
The natural killer cell immunotherapy platform: An overview of the landscape of clinical trials in liquid and solid tumors	2
Beyond SARS-CoV2, the role of viruses in the pathogenesis of hematologic malignancies	2
Palliative care needs of patients with hematologic malignancies and family caregivers and challenges of palliative care provision in Asia: A review of evidence	2
Beyond HMAs: Novel Targets and Therapeutic Approaches	2
Immunosuppressive therapy in severe aplastic anemia	2
outside front cover, PMS 8883 metallic AND 4/C	2
masthead	2
Immunocompetent mouse models of multiple myeloma	2
Cell-free DNA in large B-cell lymphoma: MRD and beyond	2